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Anti-telomerase strategiesuclear ribonucleoprotein enzyme complex that catalyzes the synthesis and
extension of telomeric DNA. This enzyme is highly expressed and active in most malignant tumors while it is
usually not or transiently detectable in normal somatic cells, suggesting that it plays an important role in
cellular immortalization and tumorigenesis. As most leukemic cells are generally telomerase-positive and
have often shortened telomeres, our understanding of how telomerase is deregulated in these diseases could
help to deﬁne novel therapies targeting the telomere/telomerase complex. Nonetheless, considering that
normal hematopoietic stem cells and some of their progeny do express a functional telomerase, it is tempting
to consider such an activity in leukemias as a sustained stemness feature and important to understand how
telomere length and telomerase activity are regulated in the various forms of leukemias.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Telomeres [1] are nucleoprotein structures composed of tandem
arrays of telomeric repeats (5′-TTAGGG-3′). They preserve genome
integrity and prevent chromosome ends from being recognized as
double-strand breaks avoiding the activation of DNA damage path-
ways that result in senescence and cell death. Telomeres of human
somatic cells shorten gradually during successive cycles of cell
division. This shortening leads to chromosomal instability and
senescence.
In contrast tomost somatic cells, stem cells, including hematopoietic
stem cells (HSCs) and some peripheral blood cells have a signiﬁcant
proliferative capacity that requires telomere length maintenance
throughout many divisions. It is achieved in part by the activity of a
specialized reverse transcriptase named telomerase which is thought to
play an important role in self-renewal of HSCs [2]. However, despite
telomerase activity, telomere shortening is not prevented but delayed
suggesting that HSCs lack sufﬁcient telomerase activity to completely
prevent telomere loss [3]. Because extinguished telomerase expression
is a constant feature of functionally mature cells, the question raised by
recent works is whether sustained telomerase activity has to be
considered as integral feature of stemness. This question is central for
cancer cell therapy, but also when considering engineered somatic cell
for cell therapy and tissue repair.
Tumor cells including leukemic cells take on properties of
undifferentiated or stem cells. These properties result from acquired
genetic/epigenetic defects in signaling pathways, making physiologi-+33 1 42 40 95 57.
.fr, evelynesegal@yahoo.fr
ll rights reserved.cal access to maturation, senescence or apoptotic program impossible.
Tumor cells, as stem cells, are endowedwith self-renewal capacity and
have lost the possibility to express a physiological mature and
functional phenotype. The current knowledge on telomere and
telomerase biology in cancer cells indicates that beside the acquisition
of genetic defects, activation of telomerase in these cells constitutes an
essential parameter in tumor progression [4–10]. Thus, telomerase/
telomere regulation represents a promising target for anticancer drug
discovery (reviewed in [11]).
Because the levels of telomerase activity vary in normal hemato-
poietic cells according to their state of differentiation and activation,
the study of telomerase deregulation in hematological malignancies
has been a difﬁcult task. The difﬁculties come from the complex
telomerase machinery and its physiological regulation and the
multiple cases of regulation evidenced by the distinct types of
hematopoietic diseases.
This paper will ﬁrst brieﬂy review our current knowledge on
telomerase machinery together with an overview of the hierarchy of
regulatory mechanisms encountered, and second, analyze the dereg-
ulation of telomerase in hematological cancers, in order to clarify the
feasibility of transferring basic research breakthrough to clinic cases
for telomerase-targeted therapeutic strategies.
2. Mechanisms of regulation of telomerase activity
Telomerase is a ribonucleoprotein complex that extends chromo-
somal ends by the addition of single-stranded TTAGGG repeats [5,8].
Telomerase consists of two components, a protein reverse transcrip-
tase (hTERT) and a RNA component (hTR), which is used as a template
for the elongation of telomeres [3,12,13]. hTR belongs to the family of
small nucleolar RNAs and contains a H/ACA domain essential for
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hTR expression shows a broad tissue distribution, telomerase activity
is generally well correlated with hTERT expression suggesting that
hTERT is a key regulator of this enzyme. However, it cannot be
excluded that the level of hTR can be limiting. Indeed, a recent study
showed that overexpression of hTR together with hTERT in cancer cell
lines and primary human ﬁbroblasts induced telomerase activity and
telomere length elongation to a higher extent than overexpression of
hTERT alone showing that hTR may be limiting in vivo [14]. Regulation
of telomerase operates at several biological levels: transcription,
splicing, hTR and hTERT modiﬁcations, enzyme trafﬁcking and
subcellular localization of each component, assembly in an active
ribonucleoprotein, accessibility and action on telomeres [15]. Not only
has telomerase a role in the prevention of senescence in highly
proliferative cells by compensating for the loss of telomeric ends,
which occurs at each cycle of replication, but it also presents non
conventional roles including capping and anti-apoptotic functions,
activation of pro-proliferative signaling pathways, and modulation of
speciﬁcation of hematopoietic stem/progenitor cells during verte-
brate development [16,17]. Furthermore, emerging evidence indicates
that beside controlling replicative lifespan and cell proliferation,
telomerase controls cell differentiation through signaling pathways
that remain to be unraveled [18–22]. Although most of these
extracurricular activities of telomerase have been reported to be
independent of its activity on telomere length maintenance, a
deﬁnitive demonstration is still lacking. Indeed, as in most of these
studies only the mean length of telomere was measured, an activity of
telomerase on critically short telomeres cannot be excluded.
Telomere structure and functions rely on two different types of
complexes, one involves in DNA elongation [23], including hTR, hTERT
and dyskerin and one involves in capping, including the shelterin
complex [24] (TRF1, TRF2, TIN2, hRAP1, TPP1, POT1). In addition to
shelterin, several DNA repair proteins present at telomeres play a
direct role in regulating telomere length and protecting telomeres
indicating an interplay between telomere function and DNA repair
[25]. Removal of telomeric proteins induces a de-protection of
telomeric DNA and dysfunction of telomeres leading to their rapid
shortening and consequently to cell death.
Regulation of telomerase activity takes place at both telomerase
protein and gene levels. The hTERT gene comprises about 35 kb DNA
and codes for an mRNA comprising 16 exons and 15 introns [26–28].
As activation of hTERT has been shown to be one important limiting
step for the induction of telomerase activity, much effort has been
focused on the understanding of the transcription regulation of hTERT.
However increasing data indicate that regulation of telomerase is a
complex process involving many steps.
2.1. Epigenetic regulation of hTERT
The hTERT promoter contains a cluster of CpG sites suggesting its
regulation to involve DNA methylation. Some groups showed the
association between the methylation status of the hTERT promoter
with gene silencing [20,29,30]. However, other reports indicated no
signiﬁcant correlation [29,31]. Furthermore, contradictory reports
have mentioned an increased DNA methylation in hTERT promoter in
hTERT-positive cancer cells while lack of methylation was found in
normal-negative cells [32]. These apparent discrepancies have been
recently solved [33,34]. In several cancer cell lines and tissues, careful
analysis of hTERT methylation patterns has demonstrated a short
region of the CpG island located in the hTERT core promoter that
remains unmethylated despite highly methylated border regions [33].
Chromatin immunoprecipitation assays have shown that active
chromatin marks in this region allow for the expression of hTERT
[34] and hTERT methylation in the border region prevents the binding
of negatively-acting transcription factors such as CTCF [35]. Recently
MBD2 (MethylCpG binding domain protein2) has been shown to bedirectly involved in transcriptional repression in hTERT-methylated
telomerase positive cells [36]. Regulation of hTERT transcription may
also involve histone acetylation/deacetylation. Trichostatin A, which
inhibits histone deacetylase, activates hTERT gene expression in
multiple cell types [37,38]. However, trichostatin A may also activate
additional genes that directly or indirectly derepress hTERT.
2.2. Transcriptional regulation of hTERT
The transcription of hTERT gene has been suggested to be the key
determinant in the regulation of telomerase activity. Transient
expression assays using the 3.0 kb of the ﬂanking sequences of the
hTERTgene revealed that the transcriptional activity was up-regulated
speciﬁcally in cancer cells, while it was silent in most normal cells
[28]. Deletion analysis of the promoter identiﬁed the proximal 260 bp
region as the core promoter essential for cancer-speciﬁc transcrip-
tional activation [26–28].
A number of binding sites for transcription factors (activators and
repressors) have been identiﬁed in the hTERT core promoter
(reviewed in [39]): two E-boxes (CACGTG located at −165 and +44
from the transcription start site) which are binding sites for basic-
helix-loop-helix zipper transcription factors encoded by the Myc
family oncogenes (Myc/Mad-1/Max); at least ﬁve GC-boxes
(GGGCGG), which are binding sites for zinc ﬁnger transcription factor
Sp1, and various cis-regulatory element that may recruit various
factors regulating hTERT transcription (Table 1). However, the
participation of many of these factors in hTERT regulation is often
deduced from studies based on overexpression and/or gene reporter
experiments, which do not mimic physiological situation.
It has been proposed that several human viruses could deregulate
telomerase transcription acting in trans as transcription factors or in
cis through viral integration (reviewed in [40]). Indeed, the integra-
tion of hepatitis B virus, papilloma virus and more recently avian
leucosis virus (ALV) in a small number of liver, cervical tumors and B
cell lymphomas have been reported suggesting that proviral integra-
tion in TERT may be of general importance in oncogenesis [41–43].
2.3. Post-transcriptional regulation of hTERT
Transcriptional activation of hTERT gene is not necessary the rate-
limiting step to generate a functional telomerase. Another regulatory
step in controlling telomerase function in cells could result from the
differential splicing of hTERT mRNA. Although the regulatory
mechanisms underlying these alternative splicing events remain
unknown, several groups have found that hTERT mRNA can exist in
a variety of splice forms [44–49]. These forms result from complete or
partial deletions of exons, or insertion of parts of introns. Alternative
splicing could therefore represent a means for cells to modulate
telomerase activity by switching their hTERT spliced variant expres-
sion proﬁles during development and in certain tumors [50–57].
Furthermore, some mechanisms of in vitro resistance to anti-
telomerase strategies could be explained by modiﬁcations in the
proﬁle of expression of these variants [58]. In the case of complete or
partial deletions of exons, hTERT RNA splicing leads to the elimination
of important motifs for the reverse transcriptase activity. These
variants should then generate truncated protein isoforms deprived of
any active role in the maintenance of telomere length. Furthermore, it
has been proposed that these splicing products, by competitive
interaction with components of the telomerase complex may act as
“dominant-negative” isoforms: so far, a dominant-negative function
has been described for the α-isoform only [44,48]. However, it has not
been investigated whether some of these variants harbor other
functions distinct from telomere maintenance. Beyond what should
be considered today as interesting speculation, the decisive question is
to clearly prove that these multiple splice variants isoforms are indeed
translated into functional proteins. Today there are only scarce
Table 1
Transcriptional and non-transcriptional factors controlling the expression of hTERT
Regulators Impact on hTERT
expression
Mode of
action
References
Transcription factors
c-Fos/c-Jun/JunD − Direct [146]
c-Myc + Direct [147,148]
Mad-1 − Direct [149–152]
Sp1 + Direct [151,153]
USF-1/2 − Direct [154]
+ Direct [155]
WT1 − Direct [156]
Ets + Direct [157]
− Direct [158]
HIF-1 + Direct [159,160]
− c-Myc [161]
NF-KB + Direct [162,163]
E2F-1 + Direct [164]
− Sp1 [165]
P53 − Sp1 [166,167]
P21/E2F [168]
P73 − c-Myc/Sp1 [169]
Rb − E2F-1/cdk2/cdk4 [170]
Hormones
Estrogen + c-Myc [171]
Direct [172,173]
Progesterone + MAP kinase [174]
−
Other factors
TGFβ − Smad3/c-Myc [175–177]
Bmi-1 + P16 [178,179]
IRF-1 − ? [180]
P16INK4a − Sp1 [181]
P27KIP1 − c-Myc/Sp1 [182]
IFNγ/IFR-1 [183]
Survivin + c-Myc/Sp1 [184]
HPV E6 + c-Myc/Sp1 [185,186]
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go further are not yet available (i.e. variant-inducible cell lines, splice
variant-speciﬁc antibodies, in cellulo functional assays for a traceable
biological response that develops over weeks…). To face a concep-
tually important question, investigators are often technically power-
less. The answer to this key question will need experimental
approaches starting from ground with relevant cellular models.
2.4. Post-translational regulation of hTERT
That it has been demonstrated the presence of apparently full-
length hTERT mRNA in samples that lack telomerase activity [59]
suggests post-translational regulation of hTERT. Modulation of
telomerase activity has been shown in response to a variety of kinase
and phosphatase inhibitors [60–63] suggesting telomerase regulation
by phosphorylation at speciﬁc serine/threonine or tyrosine residues.
It remains unclear, however, whether this modulation occurs directly
at the level of hTERT phosphorylation itself or alters indirectly
telomerase activity. Akt kinase was reported to enhance telomerase
activity through phosphorylation of hTERT [60] at Ser 824, whereas c-
Abl protein kinase inhibits telomerase activity by tyrosine phosphor-
ylation after interacting with c-Abl SH3 binding domain located in
hTERT (amino acid residues 308–316) [61].
2.5. Cellular localization of telomerase
Another important level of telomerase activity regulation is the
proper assembly of hTERT with other telomerase components and
proper localization of this complex to at least one of its sites of action,
the telomeres [64,65]. The assembly of active telomerase involves the
stabilization and transcriptional upregulation of hTR and its functionalassociation with hTERT. Processing and stability of hTR require
binding of nucleolar RNA binding proteins (H/ACA proteins) such as
dyskerin, NHP2, NOP10, and GAR1 to the H/ACA motif [66].
Subcellular transport of hTERT has also important implications in its
functional regulations. hTERT has been localized in the nucleus [67].
Yang et al. observed that hTERT protein could either be concentrated
or excluded of the nucleolus within the nucleus [68]. In another study,
both TERT and TR have been found to localize to nucleolus, leading to
the suggestion of nucleolus as the site for telomerase ribonucleopro-
tein complex biogenesis in human cells [66]. Furthermore, it was
reported that hTERT underwent a dynamic subnuclear shuttling
between nucleolus and nucleoplasm that was dependent on the cell
cycle, DNA damage or transformation [69–72]. However, this result
has been recently challenged by studies based on mutational
inactivation of a nucleolar-targeting signal that showed that although
TERT mutant did not localize in the nucleolus, it still had telomerase
activity, could maintain telomere length and did not affect cellular
proliferation [73]. This study suggests that nucleolar localization is not
related to telomerase canonical functions.
hTR was recently shown to accumulate in Cajal bodies, subnuclear
structures implicated in ribonucleoprotein maturation [70,74]. This
localization is speciﬁc to cancer cells where telomerase is active and
seems dependent on hTERT although this point remains controversial
[72,74]. Furthermore, during S phase both hTR and hTERT colocalize
within Cajal bodies that are associated with telomeres [71,75]. During
the other phases of the cell cycle, hTERT is not detected in the Cajal
bodies. These studies are very important as they suggested that Cajal
bodies, serving as sites of telomerase maturation and assembly to
deliver active telomerase to telomeres might be a key factor in
telomere length homeostasis. The assembly of the telomerase
holoenzyme is controlled by chaperone proteins helping the forma-
tion of active enzyme [76]. The Hsp90 and p23 proteins remain
permanently associated to the telomerase complex affecting its
activity.
Beside this nuclear localization of telomerase, it has recently been
demonstrated that theN terminus of hTERT has amitochondrial leader
sequence and that active telomerase can be detected in mitochondrial
extracts of hTERT overexpressing cells. Therefore telomerase has been
added to a growing list of proteins that can shuttle between the
nucleus and different subcellular compartments including mitochon-
dria [77,78]. However the biological signiﬁcance of hTERT transloca-
tion into mitochondria is still elusive and controversial.
The above observations indicate that further investigation is still
required to explore the importance of hTERT cellular localization.
Moreover, cautious has to be taken regarding the already published
results as some of themweremainly deduced from experiments using
ectopic expression of hTERT while in others direct detection of hTERT
has been performed with antibodies with low speciﬁcity if any.
Indeed, it has been recently unambiguously demonstrated that one of
the most frequently used anti-hTERT antibody, the NCL-hTERT from
Novocastra in fact recognized nucleolin rather than telomerase [79].
The conclusions previously drawn from studies using this antibody
began to be reconsidered [53,80].
2.6. Telomerase regulation by telomeric proteins and RNAs
Mammalian telomeres have been observed in a special conforma-
tion, called t-loop in which the telomere terminus is unlikely to be
accessible to telomerase. This structure is associated with telomeric
binding proteins including those of the shelterin complex which play
an important role in the regulation of telomere length as already
mentioned. TRF1 and TRF2 directly bind to the double-strand
telomere repeats. TRF1 is a negative regulator of telomere length
[81] and TFR2 is essential for telomere protection and promotion of
the t-loop [82]. POT1 which binds the single-stranded telomeric DNA
transduces the information sensed by TRF1 to telomerase resulting in
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complex with telomeric DNA that has recently been shown to
increase the activity and processivity of telomerase [84]. It has also
been shown that PARP-1 modulates telomerase activity by altering
poly-ADP-ribosylation of hTERT and/or the expression of telomerase
associated protein1 (TEP1/TP1) subunit of telomerase holoenzyme
[85]. All these observations show that having an understanding of
how telomeric proteins levels vary in tumors is fundamental for
clinical studies and may help to predict the success of treatment with
telomere-targeted agents. Finally, the newly discovered telomeric
RNAs transcribed from telomeric repeats by DNA-dependent RNA
polymerase II, TelRNAs or TERRA [86,87], block the activity of
telomerase in vitro, possibly through pairing with the template region
of hTR, suggesting that TelRNAs may regulate telomerase activity at
chromosome ends.
3. Deregulation of telomerase in hematological cancers
Several factors are important to consider for interpretation of
telomerase expression and activity levels in leukemias such as
variability among individuals and heterogeneity at the level of the
cell populations that are analyzed. The role and the mechanisms of
reactivation of telomerase in leukemic development remain currently
under debate. Telomerase positivity may occur by expansion of a pre-
existing telomerase-competent clone or alternatively by upregulation
in previously telomerase-negative cells as a consequence of genetic
instability or acquired genetic defects.
When considering hematological cancers one has ﬁrst to remind
the key feature of the developmental process of normal hemopoiesis:
a stem cell-based system, where hemopoietic stem cells have an
extraordinary capacity of self-renewal. However, this potential is fully
exploited during pathological situations, when the stem cell reservoir
has to be rapidly mobilized according to the demand of a fast
differentiating cell compartment. The steady daily hemopoiesis is in
charge of committed progenitors whose cell fate is aimed at the
production of short-life mature cells. This differentiating cell compart-
ment is exceptionally rich in cell phenotypes which when matured
have to achieve multiple biological functions (anti-bacterial, anti-
viral, anti-parasite immune responses, survey of the production of red
blood cells, phagocytes involved in cell defense and tissue clearance of
apoptotic cells, coagulation, etc…). Each of these mature cell types
exhibits a speciﬁc physiology, and requires a speciﬁc homeostatic
control of the functional population. The gain of specialized functions
is acquired at the expense of the proliferation potential. Senescence
and elimination of injured or aged cells by phagocytes, and
programmed cell death altogether contribute to avoid potentially
oncogenic events to be settled by the proliferation bursts necessary to
the clonal production of specialized hematopoietic cells. It is highly
intriguing that telomerase whose expression is observed in hemato-
poietic stem cells, progressively decreases along differentiation of
hematopoietic progenitor cells and is annihilated in short-life mature
cells. The intimate link between telomerase expression in the
hemopoietic system and the hierarchy cells with distinct self-renewal
potential observed during the developmental process, led to consider
telomerase expression and function as a matter of stemness.
Recent data suggest that telomere dysfunction can induce
environmental defects that impair the function and engraftment of
hematopoietic stem and progenitor cells [88,89]. This ﬁnding has
implications for therapy as telomere dysfunction could limit the
therapeutic potential of transplanted cells and also could contribute to
the increase cancer initiation that has been observed in aging
telomere-dysfunctional mice [90]. Indeed, the loss of telomere
functions resulting from either telomerase disorder or loss of
hematopoietic stem cells can provide selection for abnormal cells
and result in malignant progression facilitated by genomic instability
due to uncapped telomeres.Without maintenance of telomerase activity and thus telomere
maintenance, the oncogenic transformation of either myeloid stem
cells (ref. CML) or committed progenitors (ref. AML), would have little
probability to settle as a hematopoietic cancer. Therefore, the
questions as to whether 1) telomerase expression and dysregulation
take part in the etiology of hematopoietic cancers, 2) telomerase
downregulation mechanism constitutes a protection against onco-
genic events, and 3) telomerase can be a therapeutic target, cannot be
eluded. These questions can only be considered, case by case, within
each pathology context.
3.1. Myelodysplasia and acute leukemia
Several studies have investigated telomerase activity and telomere
length in total mononuclear cell populations from patients with
Myelodysplasia (MDS) and Acute Myeloid Leukemia (AML) [91,92].
Hematopoietic cells from MDS patients express low level of
telomerase [93]. This means that telomere erosion due to rapid cell
division may not be prevented in most MDS cells. This loss of telomere
stability may induce further genetic abnormalities leading to other
mutations and disease progression. MDS is a preleukemic state with
approximately 25% of patients progressing into acute myeloid
leukemia. Incidence of leukemic transformation is signiﬁcantly higher
in MDS patients with shortened telomeres. Therefore, short telomeres
without elevated telomerase activity may be a hallmark of MDS cells
and of importance in the pathogenesis of the disease. AML with
multiple chromosome aberrations are characterized by critically short
telomeres [94,95] but high telomerase activity. A recent study
performed on 40 patients during the course of acute promyelocytic
leukemia (APL) disease showed that shortened telomere length and
elevated telomerase activity correlate with disease progression and
relapse, and that this parameter may serve as prognostic factors for a
subset of APL patients with more aggressive disease who may not
respond favorably to therapy [96].
3.2. Chronic myeloid leukemia
Chronic myeloid leukemia (CML), a myeloid stem cell disease,
represents a model disorder to study the role of telomere/
telomerase biology for disease progression in a malignant stem
cell disorder. This disease is a clonal myeloproliferative disorder
characterized by the Philadelphia (Ph) chromosome, due to a
reciprocal translocation involving the long arms of chromosomes 9
and 22. This translocation generates a fusion gene, BCR-ABL, which
encodes a chimeric p210BCR/ABL protein tyrosine kinase that is
necessary and sufﬁcient for cell transformation [97]. CML is
characterized by distinct clinical phases: a relatively stable chronic
phase (CP) that can last for many years, in which mature
granulocytes are still produced even though patients have an
increased number of myeloid progenitor cells in the peripheral
blood, followed by an accelerated phase (AP). The AP, associated
with increased genetic instability and acquisition of additional
cytogenetic abnormalities, is followed by a blast crisis (BC), in which
hematopoietic differentiation has become arrested. The availability
of imatinib mesylate, a BCR-ABL tyrosine kinase inhibitor, has
revolutionized the treatment of CML [98].
Brummendorf et al. found that telomeres in Ph(+) cells are
signiﬁcantly shorter than in Ph(−) cells from the same individuals
[99]. In line with this ﬁnding, cytogenetic and molecular response
after imatinib therapy are correlated with an increase in mean
telomere length [100].
Several published studies demonstrate changes of telomere length
and telomerase activity between CP and BC. Telomerase activity has
been shown to increase in the bone marrow cells of patients with CML
during disease progression [101–104]. Telomere length is generally
shorter in AP and BC compared with serial samples taken at CP. Since
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maintain telomere length, telomere length reﬂects a proliferative
history of leukemia cells closely related to disease severity. Further-
more, it has been shown that telomere shortening observed at the
time of diagnosis signiﬁcantly inﬂuences the time of progression to AP
[99,105].
However, in other studies, it has been shown that hTERT is
downregulated in the puriﬁed CML CD34+ cells relative to the normal
CD34+ cell population and that gene expression levels of hTERT
progressively decrease with disease evolution [106]. Since previous
studies have been performed mostly on unfractionated bone marrow
samples, this discrepancy might simply reﬂect the differences in the
number of immature cells present in the sample: mononuclear
fraction in BC CML contains higher numbers of blast cells than
mononuclear fraction from normal individuals or CP CML patients. In
support of these results, Drummond et al. showed a lack of
overexpression of hTERT as well as reduction of hTR expression levels
in CD34+ cells of CP patients compared to controls [52]. These results
suggest that the increase in telomerase activity observed in patients
might actually only reﬂect the increased proportion of cycling cells in
bone marrow [52] and not a genuine increase in telomerase activity.
However, it has to be kept in mind that the CD34+ cells, immuno-
selected strictly on expression of this marker, are not identical in all
biological aspects in patient and control patients. The link between
telomerase expression and the progenitor status might prove more
subtle than initially thought. Finally, altered mRNA splicing appeared
to play a signiﬁcant role in determining functional hTERT levels and
telomere maintenance during the CP of CML and may inﬂuence the
disease progression [52] but this issue has to be analyzed in
consideration of the difﬁculties linked to approach the biology of
hTERT splice variant isoforms, as discussed above.
3.3. T-cell leukemia/lymphoma
The oncogenic human retrovirus HTLV-1 (human T-cell leukemia
virus type I) has been identiﬁed as the etiologic agent of adult T-cell
leukemia/lymphoma (ATLL), a lymphoproliferative disorder of
infected CD4+ T-cells. Several lines of evidence established that
HTLV-1 Tax protein play a central role in the conversion of normal T
cell to a leukemic cell. Similar to the pattern seen in most leukemias,
telomeres are short in HTLV-1 infected cells despite the presence of
strong telomerase activity [107–110]. The reactivation of telomerase
seems to be a key event in development and progression of ATLL. High
telomerase activity and shortened telomere length were associated
with poorer prognosis, indicating that these parameters may be useful
markers for predicting the course of disease [110].
The effect of Tax protein on expression of telomerase activity in
human cells remains controversial. One study suggested that the
HTLV-1 encoded Tax protein had a negative effect on hTERT promoter
reporter vector in transient assays [111] even though this observation
is difﬁcult to reconcile with the capacity of this protein to immortalize
T-cells. However, this repression was observed when Tax-expressing
cells were subjected to mitogenic stimulation. This result has been
challenged by recent data indicating, in contrast, that in the absence of
mitogenic stimulation, Tax stimulates the endogenous hTERT promo-
ter through the nuclear factor κB (NF-κB) signaling pathwaymediated
by Sp1 and c-Myc [112]. This discrepancy can be explained by
differences in the cell systems used but also by a cell cycle dependent
effect of Tax on hTERT expression. Indeed, a recent paper showed that
Tax activates hTERT promoter only in quiescent T-cells and not in
growing T-cells [113]. Recently, other alternative mechanisms for
telomerase activation independent of the viral Tax protein have been
identiﬁed [40,114]. One involves the HBZ (HTLV-1, bZIP factor)
identiﬁed in ATLL cells that can be responsible for the increase of
hTERT transcription during late stages of leukemogenesis. The other
one is dependent on the presence of interleukin-2 (IL-2) and involvesthe PI3K/Akt pathway. Furthermore, it has been demonstrated that IL-
2 signaling was associated with PI3K dependent/Akt independent
transcriptional up regulation of endogenous hTERT promoter. The
activation of PI3K pathway mediated cytoplasmic retention of the
Wilms tumor (WT1) protein, which strongly suppressed hTERT
promoter. This model provides an explanation for the elevated
telomerase activity in IL-2 dependent cells and ATLL patient samples
even in the absence of the HTLV1-Tax protein. It has been reported
that telomere lengths were signiﬁcantly shorter in ATLL cells, despite
expressing high telomerase activity, compared to non infected cells
isolated from the same patients [108]. This shortening of telomeres
has been associated with an increased expression of telomere binding
proteins TRF1, TRF2 and TIN2 which may increase genetic instability
and tumor progression. These results suggest that these genes could
constitute potential target for future ATLL therapy.
3.4. B-cell malignancies
B-cell chronic lymphocytic leukemia (B-CLL) results from the
progressive accumulation of a leukemia clone [115]. The identiﬁcation
of reliable prognostic markers is essential in this leukemia, which is
clinically heterogeneous. Many reports provide evidence that telo-
mere length as well as telomerase activity exerts a strong impact on
the survival of B-CLL patients. A low telomerase activity is observed at
disease onset [116] and increased activity in advanced stages and bad
prognosis groups [117]. Telomeres are shorter in B-CLL cells versus
normal B cells and especially short in patients with bad prognosis.
These observations make that telomerase activity and telomere length
can be used as new prognostic markers in this disease. A recent
transcriptome analysis of the telomere components, the shelterin
proteins andmultifactorial proteins involved in telomeremaintenance
shows both telomerase downregulation and changes in telomeric
protein compositions in peripheral B cells from 42 B-CLL patients.
However these changes have to be conﬁrmed at the protein level
[118].
A relevant role of Epstein-Barr virus (EBV) in the pathogenesis of
B-cell malignancies, including post-transplant lymphoproliferative
disorders and immunoblastic lymphoma, is strongly suggested.
Transformation of primary B-lymphocytes by EBV requires the
expression of several latent viral proteins that include six nuclear
antigens (EBNAs) and three latent membrane proteins (LMP1, LMP2A,
LMP2B). Among them LMP1 is considered as the strongest oncopro-
tein, being essential for B cells immortalization. It has been
demonstrated that activation of hTERT was associated with the
progressive increase of LMP1 expression and inhibition of viral lytic
replication [119] favoring the induction and latency in B lymphocytes.
The contribution of hTERT to EBV-driven B cell immortalization
resulted not only from preventing telomere erosion but also from
playing a crucial role in the establishment andmaintenance of a latent
infection. Although the molecular mechanisms underlying the inter-
play between EBV and hTERT need further investigation, these results
support the notion that hTERT may constitute a relevant therapeutic
target for EBV-associated B cell lymphomas.
4. Anti-telomerase strategies for leukemia
In most hematological cancers, telomere lengths are generally
shortened and telomerase deregulated. These observations are
indications that telomere length and telomerase expression and
activity can serve as molecular markers of the clinical progression and
prognosis of most leukemias. Furthermore, they raise the possibility
that anti-telomerase strategies may provide novel approaches in the
treatment of leukemia.
Since telomerase and telomere maintenance play a key role in
hematological malignancies, several approaches can be developed.
The telomerase protein complex offers multiple potential inhibitory
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transcriptional levels. Furthermore, strategies targeting telomeres as
well as approaches targeting telomerase-positive cells have also been
developed. They have already been described [11] and are summar-
ized in Table 2. Some of these anti-telomerase strategies proved to be
promising in some types of leukemia. They include both speciﬁc
compounds designed to target speciﬁcally the components of
telomerase/telomeres and already clinically relevant drugs with
telomerase-modulating properties. They will be developed below.
4.1. Drugs targeting speciﬁcally telomere/telomerase
The small molecule BIBR1532 (2-[(E)-3 naphtalen-2-yl-but-2
enoylamino]-benzoic acid), a selective, non-nucleosidic inhibitor of
the catalytic component hTERT has been shown to have direct
cytotoxic effects against primary leukemic cells from AML, CML, and
CLL patients but not against normal hematopoietic stem cells [120]. In
addition to telomerase inhibition, this compound can exert a direct
cytotoxic effect by compromising the binding of protein partners of
telomerase and telomeres resulting in their dysfunction. However,
despite initially promising this compound has not progressed into
clinical trials.
The use of speciﬁc ligands leading to G quadruplex telomeric
structure stabilization appears as a promising area of development as
they produce an anticancer effect by inhibiting the capping and
catalytic functions of telomerase and inducing the dysfunction of
telomeres by destabilizing the shelterin [121,122]. A subset of them
has been investigated in vitro on leukemic cell lines. Among them
telomestatin has been tested in acute leukemia. Decreased tumor
telomerase levels, reduced tumor volumes and marked apoptosis in
tumor tissue have been observed after systemic intraperitoneal
administration of this agent in U937 xenografts [123]. BRACO-19 is a
3, 6, 9-trisubstituted acridine compound which is shown to produce
short- and long-term growth arrest in cancer cell lines and to reduce
telomerase activity leading to long-term telomere length attrition
[124,125]. RHSP4 is a pentacyclic acridine that binds G quadruplex
DNA and inhibits telomerase activity at submicromolar levels
[126,127]. Long-term exposure of cells to low RHSP4 concentration
causes an irreversible growth arrest and telomere erosion demon-
strating that this compound possesses classical telomerase inhibitory
properties. However, used at higher doses, RHSP4 triggers short-termTable 2
Anti-telomerase strategies
Therapeutic strategies Name of the drug Applica
Oligonucleotides template antagonist GRN163/GRN163L Myelom
Renal a
Hammerhead ribozymes Human
Ovarian
Breast t
hTERT mutant Dominant negative -hTERT CML
ALL
AML
Stabilizing G-quadruplex Telomestatine (STO-095) Human
AML
Multipl
CML
BRACO-19 Uterus
RHSP4 Breast t
Immunotherapy: vaccines
targeting telomerase
(GRNVAC1, GV1001, p540–548, Vx01) Breast,
colon, l
Small molecules AZT (3-azido-2′,3′-dideoxythymidine) Adult T
B and T
BIBR 1532 AML, CC
AML, CM
Differentiation-inducing agents ATRA APL
CML
9cUAB30 AML
As2O3 APLapoptosis or senescence without telomere shortening. This effect
suggests that this compound is more than a simple telomerase
inhibitor. The short-term effect results from telomere dysfunction
[128]. This effect appears to be selective on transformed and cancer
cells as RHSP4 appears safe on normal cells. These ﬁndings validate
telomere as promising targets for future anticancer therapies and
open the door to future clinical development of this new class of
antitumor agents.
A telomere substrate antagonist, GRN163 an oligonucleotide
complementary to the telomerase RNA, and its lipid-conjugated
derivative GRN163L, inhibit telomerase activity and are active against
multiple myeloma and lymphoma [129,130]. GRN163L enters into
clinical trials in chronic lymphocytic leukemia and multiple myeloma.
Human hTERT speciﬁc epitopes are expressed on cancer cells and
not on normal cells. Owing to its expression in almost all cancers,
telomerase can thus be considered as a potential molecular target for
immunotherapy. Several therapeutic vaccines offer the potential to
stimulate the rapid killing of tumor cells by enhancing the activity of
telomerase speciﬁc cytotoxic T cells [131]. Trials have been initiated in
several types of solid tumors and in AML. To date no signiﬁcant
toxicity to normal tissues has been seen.
4.2. Already clinically relevant drugs
Since complete remission has been described in acute ATLL patients
after receiving a combination therapy including interferon (IFN) and a
reverse transcriptase inhibitor, azidothymidine (AZT) [132], it can be
suggested that drugs designed to target the reverse transcriptase
activity of hTERT may be effective for the treatment of ATLL.
Among acute myeloid leukemia, APL was found to be particularly
sensitive to differentiation therapy using ATRA (all-trans retinoic acid).
This drug induces remission of APL patients by stimulating differentia-
tion of leukemic cells [133,134] and is currently used in clinic. In our
laboratory, using the NB4 cell model for APL pathology [135], we
showed that ATRA not only transcriptionally repressed hTERT in
differentiation-associated pathway, as already demonstrated in mye-
loid HL60 cells [136] but also independently of differentiation. Indeed,
in a maturation-resistant NB4-LR1 cells, we showed that ATRA exerts
an anti-proliferative activity through hTERT downregulation, which
leads to telomere shortening and cell death [137]. It requires the co-
activation of the retinoic acid receptor alpha (RAR alpha) and thetions tested Type of cells References
a cells INA6, ARP, MM1S, OPM1, xenografts [187]
nd prostatic cells lines Caki-1, DU145 [188]
and mouse cancer cells MCF-7 [189]
cancer cells [190]
umor cells [191]
K562, OM9;22 [142,192]
HAL-01 [193]
Primary cells of AML patients [192]
leukemic monocyte lymphoma U937 [194]
NB4, U937 [123,194]
e myeloma ARD, ARP, MM1S [195]
K562 [196]
carcinoma cell line UXF1138L [124,125]
umor cells, vulva tumor cells 21NT, A431, xenografts [126–128]
prostate, pancreas, kidney,
ung
Patients with advanced
or metastatic cancers
[131,197]
-cell lymphoma HTLV-1 cell line, patients [198]
lymphoma JY616, Jurkat E6-1 [199]
L, CML HL60, JVM13, Nalm1 [120]
L Patient cells [120]
Patients [139]
Patients [139]
HL60 [200]
NB4 [141]
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also in cells, not only from patients with APL but also with other
myeloid leukemia including CML [139]. These ﬁndings are of
importance for therapy of APL but also of other leukemias because
they show that a telomerase-dependentmechanism canbe targetedby
retinoids in maturation-resistant cells. However, it has been also
shown that resistance could emerge from such a telomerase-based
therapy [140]. Interestingly, this resistance can be relieved by the
synergistic effect of ATRA/Arsenic trioxide, a treatment that triggers
downregulation of hTERT followed by telomere shortening and
subsequent cell death [141]. This observation could explain at least
partly the success of this combination therapy in APL patients. In
contrast with other antitelomerase strategies that are currently
developed (see Table 2), this telomerase-based antitumor response
operates at the level of hTERT gene transcription, therefore possibly
targeting more than one telomerase function.
Given the pathogenesis of CML, telomerase inhibition may
represent an attractive therapeutic approach. Recently the introduc-
tion of imatinib mesylate (Gleevec), an inhibitor of the BCR-ABL
tyrosine kinase activity, has strongly improved the therapy of CML
leading to signiﬁcant hematological and cytogenetic remissions and to
the increase of the mean survival time [97]. One study has demon-
strated that the ectopic expression of dominant-negative hTERT in
K562 cells enhanced apoptosis of cells compared to control treated
with imatinib [142]. It would be interesting to determine if in imatinib
resistant cell lines the expression of this dominant-negative hTERT
could overpass imatinib resistance. Furthermore, results obtained in
cell lines, although they do not allow to tell if the effect on telomerase
was direct or not, suggest that hTERToverexpressionmay be associated
with a partial escape from imatinib-induced apoptosis and that
resistance may be mediated via telomerase activation [143]. Interest-
ingly, long-term inhibition of BCR-ABL/ABL synthesis by antisense
induced telomerase activity and telomere lengthening [144]. It is
therefore not excluded that this activation can be partly responsible for
the development of resistance to BCR-ABL drugs even though this issue
has never been explored. Taken together, the role of telomerase
expression in disease progression, and imatinib resistance in CML,
including analysis of telomeres requires further investigation.
5. Conclusion
Given that deregulation of hTERT expression seems to be a general
mechanism in leukemia it is worth considering treatments targeting
telomere/telomerase biology. However, while many advances in
telomere/telomerase biology have been uncovered and many efforts
have been done to discover new anti-telomere/anti-telomerase drugs,
very few compounds are to date exploitable in clinic for reasons of low
effectiveness or toxicity in vivo and also because of our partial
knowledge on telomere and telomerase regulation and functions. It is
also becoming clear that focusing solely on a relative inhibition of
telomerase activity may misjudge the therapeutic efﬁciency of some
telomerase inhibitors. Indeed, it has been reported in some case that a
very high inhibition of telomerase activity or expression is needed to
affect telomere shortening and cell viability [145]. This requirement is
not always fulﬁlled. This feature has to be taken into account for the
development of telomerase inhibitors. Furthermore, the complexity of
telomerase regulation and malignant transformation, as well as the
variation in the clinical response from patient to patient, show clearly
that the use of a single agent could not be of therapeutic beneﬁt.
Consequently an attractive strategy would be to associate, in
combinatorial treatments, both conventional chemotherapy and
speciﬁc drugs targeting telomere/telomerase biology. Furthermore,
it would be also relevant to investigate whether clinically approved
drugs can also inﬂuence telomerase in a convergent manner. A
theoretical disadvantage of telomerase-based strategies lies in the
presence of telomerase activity in stem cells and germ cells and also inthe identiﬁcation of very low levels of telomerase activity in somatic
cells raising the possibility of side effects. This is why investigation of
telomerase expression and regulation during a stem cell development
process like hemopoiesis can deﬁnitely help to determine the
conditions for a physiological regulation of telomerase, exploiting
phenotypic variations between differentiation stages and cell lineages.
Hemopoietic tumor cells, particularly in the APL cell model, have
proved to encompass enough phenotypic plasticity to make these
subtle differences therapeutically exploitable. Finally, as it now
emerges that telomerase plays additional roles independent of
telomere maintenance, like anti-apoptotic functions possibly involved
in cancer drug resistance, the clariﬁcation of these telomerase
functions in hematopoietic cells is becoming an urgent task.
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